MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2

  • Authors:
    • Hao Zhang
    • Wenbin Ding
    • Fang Ji
    • Dajiang Wu
  • View Affiliations

  • Published online on: September 11, 2019     https://doi.org/10.3892/etm.2019.7996
  • Pages: 3659-3666
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate bone morphogenetic protein (BMP)‑2 and microRNA (miR)‑410 expression and the mechanism of regulation in serum and CD14+ peripheral blood mononuclear cells (PBMCs) from postmenopausal osteoporosis patients and model mice. A total of 26 patients with postmenopausal osteoporosis were included in the experimental group and 29 age‑matched healthy subjects were included in the control group. A total of 60 mice were divided into sham and ovariectomized (OVX) groups. Following surgery, 28 mice remained in the sham and 25 mice remained in OVX group. BMP‑2 protein expression in serum and CD14+ PBMCs from patients and model mice was determined using ELISA and western blotting, respectively. Reverse transcription‑quantitative polymerase chain reaction assays were performed to determine miR‑410 and BMP‑2 mRNA levels in serum and CD14+ PBMCs from patients and model mice. Dual luciferase reporter assays were used to identify direct interactions between miR‑410 and BMP‑2 mRNA. Compared with the control group, BMP‑2 mRNA and protein expression in serum and CD14+ PBMCs from patients with postmenopausal osteoporosis and model mice were significantly decreased. miR‑410 levels in serum and CD14+ PBMCs from patients with postmenopausal osteoporosis and model mice were significantly increased when compared with the control group. Dual luciferase reporter assays revealed that BMP‑2 was a target gene of miR‑410. The current study demonstrated that decreased BMP‑2 expression in serum and CD14+ PBMCs from patients with postmenopausal osteoporosis was associated with the upregulation of miR‑410. These results suggest that miR‑410 may participate in the pathological process of postmenopausal osteoporosis by downregulating BMP‑2.

Related Articles

Journal Cover

November 2019
Volume 18 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, H., Ding, W., Ji, F., & Wu, D. (2019). MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2. Experimental and Therapeutic Medicine, 18, 3659-3666. https://doi.org/10.3892/etm.2019.7996
MLA
Zhang, H., Ding, W., Ji, F., Wu, D."MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2". Experimental and Therapeutic Medicine 18.5 (2019): 3659-3666.
Chicago
Zhang, H., Ding, W., Ji, F., Wu, D."MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2". Experimental and Therapeutic Medicine 18, no. 5 (2019): 3659-3666. https://doi.org/10.3892/etm.2019.7996